Furthermore, while targeting LRRK2 in PD shows promise in reversing mitochondrial dysfunction, the complexity of mitochondrial pathways necessitates a more comprehensive approach tailored to individual patients [34]. This evidence concerns the gene LRRK2 and Parkinson disease.